tiprankstipranks
Taxus Cardium Pharmaceuticals Group Inc. (CRXM)
OTHER OTC:CRXM
US Market

Taxus Cardium Pharmaceuticals Group (CRXM) Stock Price & Analysis

31 Followers

CRXM Stock Chart & Stats

Day’s Range<$0.01 - <$0.01
52-Week Range― - ―
Previous Close$0.000001
Volume300.00
Average Volume (3M)N/A
Market Cap
$65.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

6.16%0.00%0.00%93.84%
6.16%
Insiders
0.00%
Mutual Funds
0.00% Other Institutional Investors
93.84% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

CRXM FAQ

What was Taxus Cardium Pharmaceuticals Group Inc.’s price range in the past 12 months?
Currently, no data Available
What is Taxus Cardium Pharmaceuticals Group Inc.’s market cap?
Currently, no data Available
When is Taxus Cardium Pharmaceuticals Group Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Taxus Cardium Pharmaceuticals Group Inc.’s earnings last quarter?
Currently, no data Available
Is Taxus Cardium Pharmaceuticals Group Inc. overvalued?
According to Wall Street analysts Taxus Cardium Pharmaceuticals Group Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
    Does Taxus Cardium Pharmaceuticals Group Inc. pay dividends?
    Taxus Cardium Pharmaceuticals Group Inc. does not currently pay dividends.
    What is Taxus Cardium Pharmaceuticals Group Inc.’s EPS estimate?
    Taxus Cardium Pharmaceuticals Group Inc.’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Taxus Cardium Pharmaceuticals Group Inc. have?
    Currently, no data Available
    What happened to Taxus Cardium Pharmaceuticals Group Inc.’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Taxus Cardium Pharmaceuticals Group Inc.?
    Currently, no hedge funds are holding shares in CRXM
    ---

    Taxus Cardium Pharmaceuticals Group Stock Smart Score

    N/A
    Not Ranked
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Company Description

    Taxus Cardium Pharmaceuticals Group Inc.

    Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease; and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA.
    ---
    Similar Stocks
    Company
    Price & Change
    Follow
    Cormedix
    Crinetics Pharmaceuticals
    Crispr Therapeutics AG
    Curis
    Popular Stocks
    ---
    What's Included in PREMIUM?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis